{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:38:17Z","timestamp":1771871897001,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013784","name":"June Hancock Mesothelioma Research Fund","doi-asserted-by":"crossref","award":["JHMRF 2014"],"award-info":[{"award-number":["JHMRF 2014"]}],"id":[{"id":"10.13039\/100013784","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"crossref","award":["APHD12-11"],"award-info":[{"award-number":["APHD12-11"]}],"id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004941","name":"Guy's and St Thomas' NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.canlet.2017.02.015","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T06:02:52Z","timestamp":1487656972000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Intracavitary \u2018T4 immunotherapy\u2019 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells"],"prefix":"10.1016","volume":"393","author":[{"given":"Astero","family":"Klampatsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Y.","family":"Achkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.","family":"Parente-Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Rosekilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thivyan","family":"Thayaparan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sheaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-4919","authenticated-orcid":false,"given":"John","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2017.02.015_bib1","first-page":"283","article-title":"Asbestos bodies and mesothelioma","volume":"11","author":"Stumphius","year":"1968","journal-title":"Ann. Occup. Hyg."},{"key":"10.1016\/j.canlet.2017.02.015_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2486\/indhealth.45.379","article-title":"Malignant mesothelioma: global incidence and relationship with asbestos","volume":"45","author":"Bianchi","year":"2007","journal-title":"Ind. Health"},{"key":"10.1016\/j.canlet.2017.02.015_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11864-014-0314-4","article-title":"Local and systemic therapies for malignant pleural mesothelioma","volume":"15","author":"Gomez","year":"2014","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.canlet.2017.02.015_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/annonc\/mdi094","article-title":"Chemotherapy options and new advances in malignant pleural mesothelioma","volume":"16","author":"Steele","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2017.02.015_bib5","doi-asserted-by":"crossref","first-page":"927240","DOI":"10.1155\/2012\/927240","article-title":"New roads open up for implementing immunotherapy in mesothelioma","volume":"2012","author":"Cornelissen","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.canlet.2017.02.015_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14737140.2016.1191951","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges","volume":"16","author":"Ceresoli","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2017.02.015_bib7","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.molonc.2015.10.012","article-title":"CAR T-cell immunotherapy: the path from the by-road to the freeway?","volume":"9","author":"Whilding","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2017.02.015_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1566523213666131223130554","article-title":"Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells","volume":"14","author":"Maher","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.canlet.2017.02.015_bib9","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2017.02.015_bib10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2017.02.015_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2017.02.015_bib12","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2017.02.015_bib13","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"T\u00a0cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.canlet.2017.02.015_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.canlet.2017.02.015_bib15","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.02.015_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2016-0008","article-title":"A\u00a0regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial","volume":"8","author":"Mayor","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2017.02.015_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/imt.16.4","article-title":"Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy","volume":"8","author":"O'Hara","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2017.02.015_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2017.02.015_bib19","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2017.02.015_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells","author":"Evans","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2017.02.015_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2017.02.015_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2017.02.015_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2010.01.002","article-title":"Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma","volume":"70","author":"Gaafar","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2017.02.015_bib24","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.02.015_bib25","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.02.015_bib26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-008-0384-4","article-title":"Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma","volume":"134","author":"Okuda","year":"2008","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.02.015_bib27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"Dazzi","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2017.02.015_bib28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1365-2559.2000.00888.x","article-title":"Immunoreactivity for cadherins, HGF\/SF, met, and erbB-2 in pleural malignant mesotheliomas","volume":"36","author":"Thirkettle","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2017.02.015_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2119\/molmed.2011.00493","article-title":"Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells","volume":"18","author":"Davies","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.canlet.2017.02.015_bib30","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.4049\/jimmunol.1301119","article-title":"Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin","volume":"191","author":"Parente-Pereira","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2017.02.015_bib31","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.4049\/jimmunol.1301523","article-title":"Preclinical in\u00a0vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?","volume":"191","author":"van der Stegen","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2017.02.015_bib32","doi-asserted-by":"crossref","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","article-title":"Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4","volume":"285","author":"Wilkie","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.02.015_bib33","first-page":"134","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor t-cells in locally advanced or recurrent head and neck cancer, human gene therapy","volume":"24","author":"van Schalkwyk","year":"2013","journal-title":"Clin. Dev."},{"key":"10.1016\/j.canlet.2017.02.015_bib34","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1158\/1078-0432.CCR-11-1808","article-title":"Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation","volume":"18","author":"Burt","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.02.015_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2017.02.015_bib36","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2017.02.015_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience","volume":"16","author":"Curran","year":"1998","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.02.015_bib38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymthe.2016.10.012","article-title":"Targeting of aberrant \u03b1v\u03b26 integrin expression in solid tumors using chimeric antigen receptor-engineered T-cells","volume":"25","author":"Whilding","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2017.02.015_bib39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10875-011-9532-8","article-title":"Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice","volume":"31","author":"Parente-Pereira","year":"2011","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.canlet.2017.02.015_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-1-4939-2727-2_21","article-title":"Clinical evaluation of ErbB-targeted CAR t-cells, following intracavity delivery in patients with ErbB-expressing solid tumors","volume":"1317","author":"Papa","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2017.02.015_bib41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-015-1881-x","article-title":"Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)","volume":"15","author":"Raynaud","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2017.02.015_bib42","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1159\/000086994","article-title":"Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma","volume":"68","author":"Mukohara","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2017.02.015_bib43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"Kawaguchi","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2017.02.015_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1749-4486.2011.02325.x","article-title":"The natural history of untreated squamous cell carcinoma of the head and neck: how we do it","volume":"36","author":"Jeannon","year":"2011","journal-title":"Clin. Otolaryngol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517301234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517301234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:11:32Z","timestamp":1589731892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383517301234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":44,"alternative-id":["S0304383517301234"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2017.02.015","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracavitary \u2018T4 immunotherapy\u2019 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2017.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}